Two recent clinical trials for untreated melanoma using a combination of nivolumab (α-programmed cell death protein-1, α-PD-1) and ipilimumab (α-CTLA-4) reported objective response rates of 53% and 61%, with complete responses seen in 11.5% and 22% of patients [2,3]. This evidence concerns the gene PDCD1 and melanoma.